Covid 19 Research using Clinical Trials (Home Page)
Lung ultrasoundWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011024 | Pneumonia, Viral NIH | 0.10 |
| D011014 | Pneumonia NIH | 0.10 |
| D018352 | Coronavirus Infections NIH | 0.03 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 3 clinical trials
Clinical Trials
1 Proposal for International Standardization of the Use of Lung Ultrasound for COVID-19 Patients; a Simple, Quantitative, Reproducible Method
Growing evidences are showing the usefulness of lung ultrasound in patients with COVID-19. Sars-CoV-2 has now spread in almost every country in the world. In this study, the investigators share their experience and propose a standardized approach in order to optimize the use of lung ultrasound in covid-19 patients. The investigators focus on equipment, procedure, classification and data-sharing.
NCT04322487 Coronavirus Epidemic Disease Pneumonia, Viral Diagnostic Test: Lung ultrasound MeSH:Pneumonia, Viral Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: Scoring procedures
Score 0: The pleura line is continuous, regular. Horizontal artifacts (A-line) are present. These artifacts are generally referred as A-lines.
Score 1: The pleura line is indented. Below the indent, vertical areas of white are visible.
Score 2: The pleura line is broken. Below the breaking point, small to large consolidated areas (darker areas) appear with associated areas of white below the consolidated area (white lung).
Score 3: The scanned area shows dense and largely extended white lung with or without larger consolidations At the end of the procedure, the clinician will write for each area the highest score obtained.
Measure: Lung ultrasound grading system for COVID-19 pneumonia Time: At enrollment.
2 Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia
Primary Outcomes
Description: Scoring procedures Score 0: The pleura line is continuous, regular. Horizontal artifacts (A-line) are present. These artifacts are generally referred as A-lines. Score 1: The pleura line is indented. Below the indent, vertical areas of white are visible. Score 2: The pleura line is broken. Below the breaking point, small to large consolidated areas (darker areas) appear with associated areas of white below the consolidated area (white lung). Score 3: The scanned area shows dense and largely extended white lung with or without larger consolidations At the end of the procedure, the clinician will write for each area the highest score obtained.
Measure: Lung ultrasound grading system for COVID-19 pneumonia Time: At enrollment.COVID-19 is a rapidly spreading and very contagious disease caused by a novel coronavirus that can lead to respiratory insufficiency. In many patients, the chest radiograph at first presentation be normal, and early low-dose CT-scan is advocated to diagnose viral pneumonia. Lung ultrasound (LUS) has similar diagnostic properties as CT for diagnosing pneumonia. However, it has the advantage that it can be performed at point-of-care, minimizing the need to transfer the patient, reducing the number of health care personnel and equipment that come in contact with the patient and thus potentially decrease the risk of spreading the infection. This study has the objective to examine the accuracy of lung ultrasound in patients with proven COVID-19 pneumonia.
NCT04338568 COVID-19 Pneumonia Lung Ultrasound Diagnostic Test: Lung ultrasound MeSH:Pneumonia
HPO:Pneumonia
Primary Outcomes
Description: The diagnostic accuracy of lung ultrasound is more than 90% compared to low-dose CT or chest X-ray for the detection of viral pneumonia in patients with COVID-19 infection.
Measure: Accuracy of the diagnosis of interstitial syndrome by lung ultrasound Time: within 2 weeks after first subject included
Description: The interobserver variability by lung ultrasound between the 2 observers for the diagnosis of interstitial syndrome by lung ultrasound is > 0.6 measured by the Kappa score
Measure: Inter-observer variability Time: within 2 weeks after first subject included
3 CORonavirus (COVID-19) Diagnostic Lung UltraSound Study
Primary Outcomes
Description: The diagnostic accuracy of lung ultrasound is more than 90% compared to low-dose CT or chest X-ray for the detection of viral pneumonia in patients with COVID-19 infection.
Measure: Accuracy of the diagnosis of interstitial syndrome by lung ultrasound Time: within 2 weeks after first subject includedDescription: The interobserver variability by lung ultrasound between the 2 observers for the diagnosis of interstitial syndrome by lung ultrasound is > 0.6 measured by the Kappa score
Measure: Inter-observer variability Time: within 2 weeks after first subject includedThis observational study is designed to assess whether focused lung ultrasound examination can improve the diagnosis of COVID-19 lung disease and/or make an alternative diagnosis at a patient's initial hospital presentation. For patients with confirmed COVID-19 the study will also assess whether surveillance lung ultrasound examination can predict clinical outcome over the course of their hospital admission.
NCT04351802 COVID-19 Diagnostic Test: Lung ultrasound MeSH:Coronavirus Infections
Primary Outcomes
Description: Primary and blinded scorer diagnosis of COVID-19 on lung ultrasound
Measure: Diagnosis of COVID-19 on lung ultrasound Time: On day of admission to hospitalDescription: Primary and blinded scorer diagnosis of COVID-19 on lung ultrasound vs. radiologist-reported chest x-ray findings
Measure: Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray Time: On day of admission to hospitalSecondary Outcomes
Description: Primary and blinded scorer diagnosis of alternative condition on lung ultrasound
Measure: Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray Time: On day of admission to hospitalDescription: Comparison of lung ultrasound findings with clinical markers of COVID-19 disease severity e.g. supplementary oxygen requirements
Measure: Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19 Time: During hospital admissionDescription: Comparison of primary and blinded scorer evaluation of lung ultrasound scans for consistency of interpretation and diagnosis
Measure: Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19 Time: On day of admission to hospital